Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Conference Call
On March 27, 2025, at 4:30 PM ET, Relmada Therapeutics, Incorporated held its Quarter 4 2024 Financial Results Call. The participants in the call were:
- Company Participants: Brian Ritchie from LifeSci Advisors, IR, Sergio Traversa, CEO, and Maged Shenouda, CFO.
- Conference Call Participants: Uy Ear from Mizuho Securities and Andrew Tsai from Jefferies.
CEO Sergio Traversa’s Remarks
Sergio Traversa began the call by expressing his gratitude to the investors for their continued support. He highlighted the Company’s achievements in the past year, including the successful completion of the pivotal trial for the treatment of fibromyalgia with dorsal root ganglion (DRG) stimulation and the receipt of a breakthrough therapy designation from the FDA. He also mentioned the progress made in the development of REL-1017, a novel, selective μ-opioid receptor agonist for the treatment of chronic pain.
CFO Maged Shenouda’s Financial Update
Maged Shenouda then presented the financial results for the quarter, highlighting the improvement in the Company’s financial position due to the successful completion of the financing round and the grant of a milestone payment from the FDA. He also discussed the anticipated milestones and expenses for the upcoming year.
Question and Answer Session
The call concluded with a question and answer session, during which the participants discussed various aspects of the Company’s business, including the regulatory path forward for REL-1017, the potential market size for the fibromyalgia indication, and the Company’s financial projections.
Impact on Individuals
For individuals living with chronic pain, the successful development of REL-1017 could mean a new and effective treatment option. The selective μ-opioid receptor agonist has the potential to provide pain relief without the addictive properties associated with traditional opioids. This could lead to improved quality of life and reduced healthcare costs for those suffering from chronic pain.
Impact on the World
The successful development and commercialization of REL-1017 could have a significant impact on the global healthcare industry. Chronic pain affects millions of people worldwide, and current treatment options often come with significant side effects and risks. A new, effective, and safe treatment for chronic pain could lead to improved patient outcomes and reduced healthcare costs.
Conclusion
In conclusion, the Q4 2024 Earnings Conference Call for Relmada Therapeutics, Incorporated provided insight into the Company’s progress in the development of new treatments for chronic pain. With the successful completion of the pivotal trial for fibromyalgia and the grant of a breakthrough therapy designation from the FDA, as well as the progress made in the development of REL-1017, the future looks promising for Relmada Therapeutics. The potential impact on individuals living with chronic pain and the global healthcare industry could be significant, with improved quality of life and reduced healthcare costs being potential benefits.
As always, it’s important to remember that the information provided in this conference call is subject to change, and investors should consult the Company’s SEC filings and other public disclosures for the most up-to-date information.
That’s all for now, folks! If you have any questions or comments, feel free to let me know.
Disclaimer: This article is for informational purposes only and should not be considered investment advice. Always do your own research and consult with a financial professional before making any investment decisions.
